Brokerages expect Insmed Incorporated (NASDAQ:INSM) to announce $39.78 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Insmed’s earnings, with estimates ranging from $34.47 million to $43.00 million. Insmed reported sales of $36.86 million during the same quarter last year, which indicates a positive year over year growth rate of 7.9%. The firm is expected to issue its next quarterly earnings report on Thursday, April 29th.
According to Zacks, analysts expect that Insmed will report full year sales of $198.56 million for the current financial year, with estimates ranging from $179.68 million to $213.90 million. For the next financial year, analysts forecast that the business will report sales of $316.14 million, with estimates ranging from $263.00 million to $373.51 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Insmed.
Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.33). Insmed had a negative net margin of 145.14% and a negative return on equity of 79.58%. The business had revenue of $41.42 million during the quarter, compared to analyst estimates of $41.44 million. During the same period in the previous year, the company posted ($0.59) earnings per share. Insmed’s revenue was down 9.4% compared to the same quarter last year.
NASDAQ INSM traded up $1.47 on Monday, reaching $35.26. The company’s stock had a trading volume of 35,169 shares, compared to its average volume of 933,382. Insmed has a twelve month low of $19.62 and a twelve month high of $45.44. The company has a debt-to-equity ratio of 1.03, a quick ratio of 7.43 and a current ratio of 7.95. The stock has a market cap of $3.64 billion, a PE ratio of -13.67 and a beta of 2.43. The firm’s 50 day moving average is $35.41 and its two-hundred day moving average is $36.95.
In related news, insider Christine A. Pellizzari sold 2,600 shares of the stock in a transaction that occurred on Tuesday, January 26th. The stock was sold at an average price of $44.04, for a total value of $114,504.00. Following the transaction, the insider now owns 155,721 shares in the company, valued at $6,857,952.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christine A. Pellizzari sold 21,550 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $44.69, for a total value of $963,069.50. Insiders sold 119,562 shares of company stock worth $4,720,810 in the last 90 days. 4.63% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Baillie Gifford & Co. bought a new stake in Insmed during the fourth quarter worth approximately $25,000. Perigon Wealth Management LLC bought a new stake in Insmed during the fourth quarter worth approximately $33,000. Penserra Capital Management LLC boosted its position in Insmed by 169.6% during the fourth quarter. Penserra Capital Management LLC now owns 2,335 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,469 shares during the period. Nisa Investment Advisors LLC boosted its position in Insmed by 32.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,745 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 1,150 shares during the period. Finally, Magnetar Financial LLC bought a new stake in Insmed during the fourth quarter worth approximately $213,000.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More: Cryptocurrencies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.